{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:53:53Z","timestamp":1792659233909,"version":"4.5.0"},"reference-count":123,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1681\/asn.2008111186","type":"journal-article","created":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T22:53:12Z","timestamp":1256856792000},"page":"2493-2502","source":"Crossref","is-referenced-by-count":242,"title":["The Role of the Mammalian Target Of Rapamycin (mTOR) in Renal Disease"],"prefix":"10.1681","volume":"20","author":[{"given":"Wilfred","family":"Lieberthal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold S.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20230410","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"R2-7-20230410","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","article-title":"Sirolimus: Its discovery, biological properties, and mechanism of action","volume":"35","author":"Sehgal","year":"2003","journal-title":"Transplant Proc"},{"key":"R3-7-20230410","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"R4-7-20230410","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"R5-7-20230410","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0952-7915(98)80172-6","article-title":"Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling","volume":"10","author":"Abraham","year":"1998","journal-title":"Curr Opin Immunol"},{"key":"R6-7-20230410","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"R7-7-20230410","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"R8-7-20230410","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat Cell Biol"},{"key":"R9-7-20230410","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"R10-7-20230410","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ceb.2006.09.005","article-title":"Thinking globally and acting locally with TOR","volume":"18","author":"Arsham","year":"2006","journal-title":"Curr Opin Cell Biol"},{"key":"R11-7-20230410","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.47.120505.105359","article-title":"mTOR pathway as a target in tissue hypertrophy","volume":"47","author":"Lee","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R12-7-20230410","doi-asserted-by":"crossref","first-page":"21110","DOI":"10.1074\/jbc.M101257200","article-title":"Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1)","volume":"276","author":"Dickson","year":"2001","journal-title":"J Biol Chem"},{"key":"R13-7-20230410","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00075197-200501000-00010","article-title":"Recent advances in the regulation of the TOR pathway by insulin and nutrients","volume":"8","author":"Avruch","year":"2005","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"R14-7-20230410","doi-asserted-by":"crossref","first-page":"G182","DOI":"10.1152\/ajpgi.00200.2004","article-title":"EGF receptor transactivation mediates ANG II-stimulated mitogensis in intestinal epithelial cells through the PI3-kinase\/Akt\/mTOR\/p70S6K1 signaling pathways","volume":"288","author":"Chiu","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R15-7-20230410","first-page":"237","article-title":"EGFR family signaling and its association with breast cancer development and resistance to chemotherapy","volume":"22","author":"Navolanic","year":"2003","journal-title":"Int J Oncol"},{"key":"R16-7-20230410","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1042\/bj20021266","article-title":"Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability","volume":"372","author":"Beugnet","year":"2003","journal-title":"Biochem J"},{"key":"R17-7-20230410","doi-asserted-by":"crossref","first-page":"14238","DOI":"10.1073\/pnas.0506925102","article-title":"Amino acids mediate mTOR\/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase","volume":"102","author":"Nobukuni","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-7-20230410","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.biochem.67.1.821","article-title":"The AMP-activated\/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell?","volume":"67","author":"Hardie","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"R19-7-20230410","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1172\/JCI200422683","article-title":"AMP-activated protein kinase: The guardian of cardiac energy status","volume":"114","author":"Hardie","year":"2004","journal-title":"J Clin Invest"},{"key":"R20-7-20230410","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1113\/jphysiol.2006.108944","article-title":"AMP-activated protein kinase: Development of the energy sensor concept","volume":"574","author":"Hardie","year":"2006","journal-title":"J Physiol"},{"key":"R21-7-20230410","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","article-title":"Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer","volume":"17","author":"Katso","year":"2001","journal-title":"Annu Rev Cell Dev Biol"},{"key":"R22-7-20230410","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tibs.2004.11.003","article-title":"Restraining PI3K: mTOR signalling goes back to the membrane","volume":"30","author":"Harrington","year":"2005","journal-title":"Trends Biochem Sci"},{"key":"R23-7-20230410","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"key":"R24-7-20230410","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0092-8674(03)00929-2","article-title":"TSC2 mediates cellular energy response to control cell growth and survival","volume":"115","author":"Inoki","year":"2003","journal-title":"Cell"},{"key":"R25-7-20230410","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev"},{"key":"R26-7-20230410","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"key":"R27-7-20230410","doi-asserted-by":"crossref","first-page":"18717","DOI":"10.1074\/jbc.M414499200","article-title":"The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses","volume":"280","author":"Smith","year":"2005","journal-title":"J Biol Chem"},{"key":"R28-7-20230410","doi-asserted-by":"crossref","first-page":"37288","DOI":"10.1074\/jbc.M303257200","article-title":"Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase\/Akt-dependent and -independent phosphorylation of tuberin","volume":"278","author":"Tee","year":"2003","journal-title":"J Biol Chem"},{"key":"R29-7-20230410","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tibs.2004.03.006","article-title":"Advances in protein kinase B signalling: AKTion on multiple fronts","volume":"29","author":"Brazil","year":"2004","journal-title":"Trends Biochem Sci"},{"key":"R30-7-20230410","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ncb840","article-title":"Akt regulates growth by directly phosphorylating TSC2","volume":"4","author":"Potter","year":"2002","journal-title":"Nat Cell Biol"},{"key":"R31-7-20230410","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"R32-7-20230410","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","article-title":"SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity","volume":"127","author":"Jacinto","year":"2006","journal-title":"Cell"},{"key":"R33-7-20230410","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.devcel.2006.09.005","article-title":"mTORC2 caught in a SINful Akt","volume":"11","author":"Polak","year":"2006","journal-title":"Dev Cell"},{"key":"R34-7-20230410","doi-asserted-by":"crossref","first-page":"40406","DOI":"10.1074\/jbc.M508361200","article-title":"mTOR.RICTOR is the Ser473 kinase for Akt\/protein kinase B in 3T3\u2013L1 adipocytes","volume":"280","author":"Hresko","year":"2005","journal-title":"J Biol Chem"},{"key":"R35-7-20230410","doi-asserted-by":"crossref","first-page":"E980","DOI":"10.1152\/ajpendo.00333.2004","article-title":"Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside","volume":"288","author":"Reiter","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R36-7-20230410","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.995802","article-title":"Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1\/eIF4E","volume":"16","author":"Fingar","year":"2002","journal-title":"Genes Dev"},{"key":"R37-7-20230410","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Fingar","year":"2004","journal-title":"Mol Cell Biol"},{"key":"R38-7-20230410","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1101\/gad.887201","article-title":"Regulation of translation initiation by FRAP\/mTOR","volume":"15","author":"Gingras","year":"2001","journal-title":"Genes Dev"},{"key":"R39-7-20230410","first-page":"169","article-title":"mTOR signaling to translation","volume":"279","author":"Gingras","year":"2004","journal-title":"Curr Top Microbiol Immunol"},{"key":"R40-7-20230410","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2353\/ajpath.2007.070412","article-title":"Regulation of elongation phase of mRNA translation in diabetic nephropathy: Amelioration by rapamycin","volume":"171","author":"Sataranatarajan","year":"2007","journal-title":"Am J Pathol"},{"key":"R41-7-20230410","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1093\/emboj\/16.12.3693","article-title":"Rapamycin suppresses 5\u2032TOP mRNA translation through inhibition of p70s6k","volume":"16","author":"Jefferies","year":"1997","journal-title":"EMBO J"},{"key":"R42-7-20230410","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","article-title":"mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events","volume":"123","author":"Holz","year":"2005","journal-title":"Cell"},{"key":"R43-7-20230410","doi-asserted-by":"crossref","first-page":"F3","DOI":"10.1152\/ajprenal.2000.279.1.F3","article-title":"Acute renal failure: III. The role of growth factors in the process of renal regeneration and repair","volume":"279","author":"Nigam","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"R44-7-20230410","doi-asserted-by":"crossref","first-page":"F810","DOI":"10.1152\/ajprenal.00078.2002","article-title":"Coordination of the cell cycle is an important determinant of the syndrome of acute renal failure","volume":"283","author":"Megyesi","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"R45-7-20230410","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1172\/JCI117214","article-title":"Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney: Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells","volume":"93","author":"Witzgall","year":"1994","journal-title":"J Clin Invest"},{"key":"R46-7-20230410","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/01.ASN.0000067652.51441.21","article-title":"Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure","volume":"14","author":"Bonventre","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R47-7-20230410","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1016\/S0041-1345(03)00356-7","article-title":"The rapamune era of immunosuppression 2003: The journey from the laboratory to clinical transplantation","volume":"35","author":"Camardo","year":"2003","journal-title":"Transplant Proc"},{"key":"R48-7-20230410","doi-asserted-by":"crossref","first-page":"F693","DOI":"10.1152\/ajprenal.2001.281.4.F693","article-title":"Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells","volume":"281","author":"Lieberthal","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"R49-7-20230410","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/01.tp.0000225772.22757.5e","article-title":"Rapamycin delays but does not prevent recovery from acute renal failure: Role of acquired tubular resistance","volume":"82","author":"Lieberthal","year":"2006","journal-title":"Transplantation"},{"key":"R50-7-20230410","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/01.ASN.0000057542.86377.5A","article-title":"Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use","volume":"14","author":"Smith","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R51-7-20230410","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-6143.2003.00078.x","article-title":"Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation","volume":"3","author":"McTaggart","year":"2003","journal-title":"Am J Transplant"},{"key":"R52-7-20230410","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/01.TP.0000095897.38634.30","article-title":"Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury","volume":"76","author":"Fuller","year":"2003","journal-title":"Transplantation"},{"key":"R53-7-20230410","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.transproceed.2007.01.027","article-title":"The role of immunosuppressive drugs in aggravating renal ischemia and reperfusion injury","volume":"39","author":"Goncalves","year":"2007","journal-title":"Transplant Proc"},{"key":"R54-7-20230410","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"R55-7-20230410","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1097\/01.ASN.0000139932.00971.E4","article-title":"Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: Differential modulation by rapamycin","volume":"15","author":"Loverre","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R56-7-20230410","first-page":"359","article-title":"Diabetic nephropathy: Pathogenesis, diagnosis, and prevention of progression","volume":"46","author":"Estacio","year":"2001","journal-title":"Adv Intern Med"},{"key":"R57-7-20230410","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.2337\/diacare.27.2007.S79","article-title":"Nephropathy in diabetes","volume":"27","author":"Molitch","year":"2004","journal-title":"Diabetes Care"},{"key":"R58-7-20230410","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMra022161","article-title":"Polycystic kidney disease","volume":"350","author":"Wilson","year":"2004","journal-title":"N Engl J Med"},{"key":"R59-7-20230410","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev.ph.57.030195.001403","article-title":"Progression of renal disease and renal hypertrophy","volume":"57","author":"Hostetter","year":"1995","journal-title":"Annu Rev Physiol"},{"key":"R60-7-20230410","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/snep.2003.50017","article-title":"Hyperfiltration and glomerulosclerosis","volume":"23","author":"Hostetter","year":"2003","journal-title":"Semin Nephrol"},{"key":"R61-7-20230410","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1681\/ASN.2004100894","article-title":"Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy","volume":"16","author":"Chen","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R62-7-20230410","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1681\/ASN.2006050488","article-title":"mRNA translation: Unexplored territory in renal science","volume":"17","author":"Kasinath","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R63-7-20230410","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2337\/db05-1334","article-title":"High glucose, high insulin, and their combination rapidly induce laminin-beta1 synthesis by regulation of mRNA translation in renal epithelial cells","volume":"56","author":"Mariappan","year":"2007","journal-title":"Diabetes"},{"key":"R64-7-20230410","doi-asserted-by":"crossref","first-page":"R592","DOI":"10.1152\/ajpregu.00207.2007","article-title":"Hyperglycemia impairs glucose and insulin regulation of nitric oxide production in glucose-inhibited neurons in the ventromedial hypothalamus","volume":"293","author":"Canabal","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R65-7-20230410","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.metabol.2005.05.010","article-title":"Elevated glucose activates protein synthesis in cultured cardiac myocytes","volume":"54","author":"Yeshao","year":"2005","journal-title":"Metabolism"},{"key":"R66-7-20230410","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling","year":"2007","journal-title":"Cancer Res"},{"key":"R67-7-20230410","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.diabres.2008.09.028","article-title":"Role of TSC-mTOR pathway in diabetic nephropathy","volume":"82","author":"Inoki","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"R68-7-20230410","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/db07-0922","article-title":"mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes","volume":"57","author":"Fraenkel","year":"2008","journal-title":"Diabetes"},{"key":"R69-7-20230410","doi-asserted-by":"crossref","first-page":"F617","DOI":"10.1152\/ajprenal.00278.2006","article-title":"A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy","volume":"292","author":"Lee","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R70-7-20230410","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bbrc.2005.12.012","article-title":"Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice","volume":"340","author":"Sakaguchi","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"R71-7-20230410","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000106782","article-title":"Rapamycin prevents early steps of the development of diabetic nephropathy in rats","volume":"27","author":"Yang","year":"2007","journal-title":"Am J Nephrol"},{"key":"R72-7-20230410","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1681\/ASN.2005050549","article-title":"Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats","volume":"17","author":"Lloberas","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R73-7-20230410","doi-asserted-by":"crossref","first-page":"F76","DOI":"10.1152\/ajprenal.00128.2006","article-title":"Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production","volume":"292","author":"Lock","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R74-7-20230410","doi-asserted-by":"crossref","first-page":"23166","DOI":"10.1074\/jbc.M401238200","article-title":"Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway","volume":"279","author":"Shegogue","year":"2004","journal-title":"J Biol Chem"},{"key":"R75-7-20230410","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1074\/jbc.275.6.4336","article-title":"Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts","volume":"275","author":"Brenneisen","year":"2000","journal-title":"J Biol Chem"},{"key":"R76-7-20230410","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev.med.57.121304.131342","article-title":"Toward a unified theory of renal progression","volume":"57","author":"Harris","year":"2006","journal-title":"Annu Rev Med"},{"key":"R77-7-20230410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.ASN.0000106015.29070.E7","article-title":"Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention","volume":"15","author":"Liu","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R78-7-20230410","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1083\/jcb.200611146","article-title":"Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway","volume":"178","author":"Lamouille","year":"2007","journal-title":"J Cell Biol"},{"key":"R79-7-20230410","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1158\/0008-5472.CAN-07-6302","article-title":"p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells","volume":"68","author":"Pon","year":"2008","journal-title":"Cancer Res"},{"key":"R80-7-20230410","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1681\/ASN.2006070704","article-title":"Chronic kidney disease progression","volume":"17","author":"Eddy","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R81-7-20230410","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1038\/sj.ki.5000161","article-title":"Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis","volume":"69","author":"Wu","year":"2006","journal-title":"Kidney Int"},{"key":"R82-7-20230410","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1681\/ASN.2007010087","article-title":"Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass","volume":"18","author":"Diekmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R83-7-20230410","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00041552-199805000-00009","article-title":"Biology of ischemic and toxic renal tubular cell injury: Role of nitric oxide and the inflammatory response","volume":"7","author":"Lieberthal","year":"1998","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R84-7-20230410","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1681\/ASN.2004030180","article-title":"Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy","volume":"16","author":"Bonegio","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R85-7-20230410","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2353\/ajpath.2007.060497","article-title":"Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin","volume":"170","author":"Schaefer","year":"2007","journal-title":"Am J Pathol"},{"key":"R86-7-20230410","doi-asserted-by":"crossref","first-page":"F440","DOI":"10.1152\/ajprenal.00379.2007","article-title":"Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat","volume":"294","author":"Kramer","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"R87-7-20230410","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1097\/01.ASN.0000028643.17901.42","article-title":"Genetics and pathogenesis of polycystic kidney disease","volume":"13","author":"Igarashi","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R88-7-20230410","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1067\/mlc.2003.13","article-title":"Autosomal dominant polycystic kidney disease: Molecular genetics and pathophysiology","volume":"141","author":"Sutters","year":"2003","journal-title":"J Lab Clin Med"},{"key":"R89-7-20230410","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/j.1523-1755.2005.00201.x","article-title":"Molecular pathogenesis of ADPKD: The polycystin complex gets complex","volume":"67","author":"Ong","year":"2005","journal-title":"Kidney Int"},{"key":"R90-7-20230410","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2184.2008.00529.x","article-title":"Novel role for polycystin-1 in modulating cell proliferation through calcium oscillations in kidney cells","volume":"41","author":"Aguiari","year":"2008","journal-title":"Cell Prolif"},{"key":"R91-7-20230410","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2215\/CJN.05611207","article-title":"Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease","volume":"3","author":"Edelstein","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R92-7-20230410","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1681\/ASN.2006121378","article-title":"Caspase-3 gene deletion prolongs survival in polycystic kidney disease","volume":"19","author":"Tao","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R93-7-20230410","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.coph.2005.04.016","article-title":"Emerging therapies for polycystic kidney disease","volume":"5","author":"Gattone","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"R94-7-20230410","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.pharmtox.41.1.175","article-title":"The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists","volume":"41","author":"Thibonnier","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R95-7-20230410","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1992.tb09058.x","article-title":"Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist","volume":"105","author":"Yamamura","year":"1992","journal-title":"Br J Pharmacol"},{"key":"R96-7-20230410","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R97-7-20230410","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"R98-7-20230410","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5002550","article-title":"VEGF receptor inhibition slows the progression of polycystic kidney disease","volume":"72","author":"Tao","year":"2007","journal-title":"Kidney Int"},{"key":"R99-7-20230410","doi-asserted-by":"crossref","first-page":"8394","DOI":"10.1073\/pnas.84.23.8394","article-title":"Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease","volume":"84","author":"Cowley","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R100-7-20230410","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1992.44","article-title":"Localization of overexpressed c-myc mRNA in polycystic kidneys of the cpk mouse","volume":"41","author":"Harding","year":"1992","journal-title":"Kidney Int"},{"key":"R101-7-20230410","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ki.1991.80","article-title":"C-myc as an inducer of polycystic kidney disease in transgenic mice","volume":"39","author":"Trudel","year":"1991","journal-title":"Kidney Int"},{"key":"R102-7-20230410","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic disease","volume":"16","author":"Tao","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R103-7-20230410","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","author":"Wahl","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R104-7-20230410","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R105-7-20230410","first-page":"25","article-title":"Therapeutic interventions for autosomal dominant polycystic kidney disease","volume":"22","author":"Edelstein","year":"2008","journal-title":"Nephrol News Issues"},{"key":"R106-7-20230410","first-page":"257","article-title":"New therapeutic prospects in autosomal dominant polycystic kidney disease","volume":"28","author":"Torra","year":"2008","journal-title":"Nefrologia"},{"key":"R107-7-20230410","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/sj.bjc.6602978","article-title":"Targeted therapy for metastatic renal cell carcinoma","volume":"94","author":"Patel","year":"2006","journal-title":"Br J Cancer"},{"key":"R108-7-20230410","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MOU.0b013e3282c508e0","article-title":"Recent advances in targeted therapy for renal cell carcinoma","volume":"17","author":"Clark","year":"2007","journal-title":"Curr Opin Urol"},{"key":"R109-7-20230410","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2008.07.007","article-title":"New therapeutic developments in renal cell cancer","volume":"69","author":"Prenen","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"R110-7-20230410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2006.08.003","article-title":"Anti-angiogenic therapy in the treatment of advanced renal cell cancer","volume":"33","author":"Board","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"R111-7-20230410","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1358\/dot.2007.43.10.1148059","article-title":"Temsirolimus","volume":"43","author":"Ma","year":"2007","journal-title":"Drugs Today (Barc"},{"key":"R112-7-20230410","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1634\/theoncologist.12-12-1404","article-title":"Renal cell carcinoma: New developments in molecular biology and potential for targeted therapies","volume":"12","author":"Costa","year":"2007","journal-title":"Oncologist"},{"key":"R113-7-20230410","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"7","author":"Garcia","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"R114-7-20230410","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","article-title":"Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin","volume":"22","author":"Hudson","year":"2002","journal-title":"Mol Cell Biol"},{"key":"R115-7-20230410","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.cellbio.15.1.551","article-title":"Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1","volume":"15","author":"Semenza","year":"1999","journal-title":"Annu Rev Cell Dev Biol"},{"key":"R116-7-20230410","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0093-7754(01)90211-8","article-title":"Biological consequences of tumor hypoxia","volume":"28","author":"Hockel","year":"2001","journal-title":"Semin Oncol"},{"key":"R117-7-20230410","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0959-437X(00)00152-0","article-title":"The von Hippel-Lindau tumor suppressor protein","volume":"11","author":"Ivan","year":"2001","journal-title":"Curr Opin Genet Dev"},{"key":"R118-7-20230410","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1158\/1078-0432.CCR-07-0411","article-title":"Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma","volume":"13","author":"Klatte","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R119-7-20230410","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1034>3.0.CO;2-S","article-title":"PTEN\/MMAC1\/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines","volume":"91","author":"Kondo","year":"2001","journal-title":"Int J Cancer"},{"key":"R120-7-20230410","first-page":"5645","article-title":"Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors","volume":"62","author":"Kenerson","year":"2002","journal-title":"Cancer Res"},{"key":"R121-7-20230410","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","article-title":"TSC2 regulates VEGF through mTOR-dependent and -independent pathways","volume":"4","author":"Brugarolas","year":"2003","journal-title":"Cancer Cell"},{"key":"R122-7-20230410","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus","volume":"66","author":"Del Bufalo","year":"2006","journal-title":"Cancer Res"},{"key":"R123-7-20230410","doi-asserted-by":"crossref","first-page":"39653","DOI":"10.1074\/jbc.M306104200","article-title":"AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells","volume":"278","author":"Lee","year":"2003","journal-title":"J Biol Chem"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-200912000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:31:53Z","timestamp":1786131113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-200912000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":123,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2008111186","relation":{},"ISSN":["1046-6673"],"issn-type":[{"value":"1046-6673","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}